Designing a Long Acting Erythropoietin by Fusing Three Carboxyl-Terminal Peptides of Human Chorionic Gonadotropin 𝜷 Subunit to the N-Terminal and C-Terminal Coding Sequence

Figure 5

In vivo bioactivity of recombinant HuEPO derivatives. ICR mice (𝑛=7/group) received a single IV injection/week (15 mg/kg) for three weeks of EPO-WT, rHuEPO, or EPO-(CTP)₃. In addition, mice were treated with 5 μg/kg of rHuEPO three times a week for 3 weeks. Control animals were injected IV with saline. Blood samples were collected three times a week and haematocrit levels were detected. Each point represents the group average of haematocrit (%) ± SE. *𝑃<0.0.5, **𝑃<0.01, and ***𝑃<0.001.